digital pathology
The companies said the aim of the partnership is to address the pressure pathologists face due to the global shortage of pathologists and the increasing number of cancer patients.
AI will be integrated to increase pathologists' efficiency.
The partnership will initially be used to distribute PathAI’s research-use-only algorithm focusing on immuno-oncology.
IntelliSite is designed to streamline workflows, enhance diagnostic confidence, facilitate collaboration, integrate AI and increase the efficiency of pathology labs.
Paige Prostate analyzes digitized biopsy slides and identifies areas that could be cancerous for the pathologist to review further.
Also: Opya scooped up $15.4 million, MiSalud raised $5 million and DocSpace announced $1.2 million in seed funding.
The companies will combine their complementary pathology tools to leverage services for tech-enabled diagnostics, drug discovery and patient care.
The Boston-based company has now raised a hair over $90 million for its AI pathology platform.
The Boston-based company has grown from 25 to 60 staff members within the past year, and has collaborated with pharmaceutical partners such as Bristol-Myers Squibb and Novartis.
The Series A round comes just half a year after the Columbus, Ohio-based startup's prior fundraise.